The red finger comes from the "The Russians are Coming. The Russians are Coming" short who tried to downplay the historic Ph1b PegpH20 results based on XENOPHOBIA.
ASCO GI 1/16/15 BOARD C28 session 5
Final results Ph Ib study of Gem plus PEGPH20 in pts with stage IV previously untreated pancreatic cancer
Abstract #359 Hingorani Halozyme
Further raising the possibility that They are the new party negotiating for Enhanze rights with HALO.
My pleasure- It's gratifying to see the vast majority of Enhanze plans come to fruition- next it's IV version- PegpH20!
That's not my handle - (all wrong)- btw- Congratulations on finding the Unannounced mabTheraSC Australian pre EU launch and the pediatric formulary of HyQvia pre launch, as well as the statement from a professor of Pediatrics that HyQvia will indeed be used in children, and the FDA approval allowing it without near term reporting.
PCYC and GILD both have oral Drugs in competition w Arzerra and Gazyva- who will be left standing when the music stops?
2006 Deal "$111M for 1st 3 targets-Herceptin/Actemra(tried but discontinued) Mabthera- For ea of the addn'l 10 Targets Roche may pay Halozyme up to $47 million per target" = Gazyva would come under this next price per target. A rise in royalties is possible as well.
WAIT a Second- 1st 3 targets included in initial milestone and other upfront payments- that's Herceptin, Actemtra- which was investgated w Enhaze thwn dropped for no adjunct subcut agent- and MAbThera- SO Gazvya Would be the beginning of another "deal" - hope it's all of the above"
" Pending the successful completion of a series of
clinical, regulatory, and sales events, Roche may pay Halozyme further
milestones which could potentially reach a value of up to $111 million as well as royalties on potential product sales for the first three targets.
For each of the additional ten targets, Roche may pay Halozyme further
upfront and milestone payments of up to $47 million per target."
I believe you are right- I stil think Gazvya is getting Enhanze- as Torley agreed with Citi's Beatty on expansion of Enhanze activity with Gazvya - on tape- but she ALSO earler in the call mentioned Increased interest from other companies- I think that could mean GSK- more on that tomorrow.
"All abstracts part of the 2015 Gastrointestinal Cancers Symposium remain confidential in accordance with ASCO’s Confidentiality Policy until they are publicly released online at gicasym. org at 5:00 PM Eastern Time on Monday, January 12, 2015."
Thompson StreetEvents Transcript has Gazyva as "Godiva"- getting closer! But Obviously Gazvya is what Analyst Beatty of Citibank said he heard Roche teaming with Enhance- most likely due to October NICE rejection of IV Gazvya.
Last Question Q3 14 Earnings Call - Torley understands and agrees 2015 will be a busy yr for HALO
Halozyme Therapeutics meets 3Q profit forecasts
Mon, 10 Nov '14 | 6:51 PM ET
The Associated Press
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
On a per-share basis, the San Diego-based company said it had a loss of 16 cents.
The results met Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was also for a loss of 16 cents per share.
BMO Analyst Jim Birchenough MD called for turning HALO into small Cancer co.- shares Torley's Focus- She stated in Q3 14 Call that PegpH20 was her reason for coming from Amgen/Onyx (another small cancer Co.)
If 13% of workforce is 22 jobs-then 147 still work at HALO. That's $920,000 per employee-cash on hand with 4 Ph2 trials-2 Paid by NCI+MSKCC Lung starting in Dec and then Breast Cancer Next- BMO Reiterated Outperform and cheered the moves- upholding $24 PT- called Peg a "Potential Backbone Adjunct"